Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 60,000 shares at $16.31 ($913K) on 2024-09-03, disclosed to the SEC on 2024-09-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.03 | 10,000 | $140K | 15.4% |
| 2 | $14.02 | 10,000 | $140K | 15.4% |
| 3 | $15.66 | 15,288 | $239K | 26.2% |
| 4 | $15.66 | 15,288 | $239K | 26.2% |
| 5 | $16.31 | 4,712 | $77K | 8.4% |
| 6 | $16.31 | 4,712 |
| $77K |
| 8.4% |
| Total | $15.22 avg | 60,000 | $913K | 100% |
| Filing → |
| INBX | BUY | 2024-09-10 | $671K | — | Filing → |
| INBX | BUY | 2024-08-22 | $1.0M | — | Filing → |
| INBX | SELL | 2023-03-01 | $2K | — | Filing → |